



Attorney's Docket No.: R0547/7007(ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: LIAO, James K.; LAUFS, Ulrich; ENDRES, Matthias; and MOSKOWITZ, Michael A.  
Filing Date: March 19, 1999  
Serial No.: 09/273,445  
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE  
BY HMG-CoA REDUCTASE INHIBITORS  
Examiner: Not Assigned  
Art Unit: 1646

pre 5/a

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Assistant Commissioner for Patents, Attention: Box Missing Parts, Washington, D.C. 20231, on the 28th day of July, 1999.

Signature:

*Jill R. Clarke*

Printed Name:

Jill R. Clarke

THE ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Before calculating the fees, please amend the above-identified application as follows:

In the Claims

Prior to calculating the claim fees please amend the claims as follows:

Please cancel claims 25, 30-40, 42-45, 50-90, 116-130, 134-155, 159-166, 175, and 176.

✓ Please amend claims 26, 41, 97, 99, 103, 108, 177, 181, 182, 187, 192, and 193. ✓

26. (Amended) The method of claim[s] [1- 25] 1, further comprising co-administering an endothelial cell Nitric Oxide Synthase substrate.

41. (Amended) The method of claim[s] [1- 25] 1, further comprising co-administering at least one different HMG-CoA reductase inhibitor that increases endothelial cell Nitric Oxide Synthase activity.

97. (Amended) The method of claim[s] [91- 96] 91, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of simvastatin and lovastatin.

09E73445

00000151 232825

55.00 CH

08/03/1999 TL0011

05 FC:215